-
公开(公告)号：US20220193129A1
公开(公告)日：2022-06-23
申请号：US16607962
申请日：2018-04-27
申请人： Immusoft Corporation
摘要： The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as a therapeutic protein. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of a therapeutic agent.
-
公开(公告)号：US20230013198A1
公开(公告)日：2023-01-19
申请号：US17735676
申请日：2022-05-03
申请人： IMMUSOFT CORPORATION
发明人： Mei XU , Matthew Rein SCHOLZ , Eric J. HERBIG
IPC分类号： C12N5/0781
摘要： The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
-
公开(公告)号：US11103582B2
公开(公告)日：2021-08-31
申请号：US15863740
申请日：2018-01-05
申请人： IMMUSOFT CORPORATION
发明人： R. Scott McIvor , Perry B. Hackett , Jason Bell , Myra Christine Urness-Rusten , Elena Aronovich , David W. Hunter
IPC分类号： A61K48/00 , A61K47/02 , A61K31/353 , A61K31/663 , A61K33/00 , A61K9/00 , A61K38/18 , A61K38/37 , A61K38/48
摘要： Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.
-
公开(公告)号：US10240125B2
公开(公告)日：2019-03-26
申请号：US14776283
申请日：2014-03-14
申请人： Immusoft Corporation
发明人： Mei Xu , Matthew Rein Scholz , Eric J. Herbig
IPC分类号： C12N5/00 , C12N15/86 , C12N5/0781 , A61K48/00
摘要： The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
-
公开(公告)号：US20180185487A1
公开(公告)日：2018-07-05
申请号：US15863740
申请日：2018-01-05
申请人： IMMUSOFT CORPORATION
发明人： R. Scott MCIVOR , Perry B. HACKETT , Jason BELL , Myra Christine URNESS-RUSTEN , Elena ARONOVICH , David W. HUNTER
IPC分类号： A61K47/02 , A61K31/663 , A61K31/353 , A61K48/00 , A61K33/00 , A61K9/00 , A61K38/18 , A61K38/37 , A61K38/48
CPC分类号： A61K47/02 , A61K9/0019 , A61K31/353 , A61K31/663 , A61K33/00 , A61K38/1816 , A61K38/37 , A61K38/4846 , A61K48/0008 , A61K48/0075 , A61K48/0083 , A61K2300/00
摘要： Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.
-
6.发明公开公开(公告)号：US20230414659A1
公开(公告)日：2023-12-28
申请号：US18034865
申请日：2021-10-29
申请人： Immusoft Corporation
发明人： Christiane S. HAMPE
IPC分类号： A61K35/17 , C12N5/0781 , C12N9/24 , A61P3/00 , A61K9/00
CPC分类号： A61K35/17 , C12N5/0635 , C12N9/2402 , C12Y302/01075 , A61P3/00 , A61K9/0085 , C12N2510/00
摘要： Provided herein are methods for administering engineered B cells to produce a therapeutic agent in vivo. In various embodiments, engineered B cells are directly administered to the central nervous system (CNS). The compositions and methods disclosed herein may be used for enzyme replacement therapy, for example, treatment of diseases or disorders associated with lysosomal storage dysfunction through production of iduronidase (IDUA).
-
7.发明申请公开(公告)号：US20190241870A1
公开(公告)日：2019-08-08
申请号：US16267150
申请日：2019-02-04
申请人： IMMUSOFT CORPORATION
发明人： Mei XU , Matthew Rein SCHOLZ , Eric J. HERBIG
IPC分类号： C12N5/0781
CPC分类号： C12N5/0635 , C12N2501/2302 , C12N2501/2306 , C12N2501/231 , C12N2501/2315 , C12N2501/24 , C12N2501/52 , C12N2510/02
摘要： The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
-
8.发明申请METHODS FOR IN VITRO MEMORY B CELL DIFFERENTIATION AND TRANSDUCTION WITH VSV-G PSEUDOTYPED VIRAL VECTORS 审中-公开用VSV-G PSEUDOTYPED VIRAL VECTORS进行体外记忆B细胞分化和转导的方法公开(公告)号：US20160046908A1
公开(公告)日：2016-02-18
申请号：US14776283
申请日：2014-03-14
申请人： IMMUSOFT CORPORATION
发明人： Mei Xu , Matthew Rein Scholz , Eric J. Herbig
IPC分类号： C12N5/0781
CPC分类号： C12N5/0635 , C12N2501/2302 , C12N2501/2306 , C12N2501/231 , C12N2501/2315 , C12N2501/24 , C12N2501/52 , C12N2510/02
摘要： The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
摘要翻译： 本公开涉及记忆B细胞到浆细胞或浆细胞的体外分化以及这些细胞的遗传修饰以表达目的蛋白，例如特异性抗体或其它蛋白质治疗剂。
-
公开(公告)号：US20230081163A1
公开(公告)日：2023-03-16
申请号：US17886337
申请日：2022-08-11
申请人： Immusoft Corporation
发明人： Matthew Rein SCHOLZ , Eric J. HERBIG , Mei XU , Rian DE LAAT
IPC分类号： C12N5/0781 , C12N5/00 , A61K35/17
摘要： The present disclosure relates to genetically modified B cells, including memory cells, differentiated to plasmablasts or plasma cells useful for long term in vivo expression of a transgene, such as a specific antibody or other protein therapeutic. Also disclosed are methods of producing the cells and methods of treatment.
-
10.发明授权公开(公告)号：US11352603B2
公开(公告)日：2022-06-07
申请号：US16267150
申请日：2019-02-04
申请人： IMMUSOFT CORPORATION
发明人： Mei Xu , Matthew Rein Scholz , Eric J. Herbig
IPC分类号： C12N15/86 , C12N5/00 , C12N5/0781 , A61K48/00
摘要： The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.013 秒)
